A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » IAS 2011

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


July 21, 2011

VIRxSYS Vaccine 'Functionally' Cures Two Monkeys in Recent Study

by Tim Horn

Encouraging preliminary results involving a vaccine being developed by Maryland-based VIRxSYS Corporation were presented Monday, July 18, at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome. Two of five monkeys given the vaccine and then exposed to a primate version of HIV show early signs of being functionally cured, based on blood measurements of viral load, along with measurements of simian immunodeficiency virus (SIV) in blood and tissue cells.

While preventive vaccines are generally designed to prevent infections from establishing in the body, another approach is to develop a vaccine that helps the immune system control, but not eradicate, a virus—a functional cure, should infection be established. Vaccines of this nature are also be explored for treatment purposes, notably to achieve functional cures in those already infected with HIV. 

VIRxSYS is exploring the use of lentiviruses—HIV is a lentivirus—to deliver genetic materials to cells that can trigger an immune response. Simply put, the company guts the virus, removing all disease-causing elements, ultimately preserving the viral proteins necessary to spark the immune system.
The study reported at IAS, under the direction of Franck Lemiale, PhD, of VIRxSYS, involved a vaccine dubbed VRX116, a SIV version of the company’s lentiviral vaccine being explored in humans: VRX1273. Five macaques received three injections of the vaccine during an 18-week period, and five received inactive vaccines. One of the monkeys, in the control group, had carried genes consistent with SIV immune system control and survival—in other words, that monkey was an elite controller.

The vaccine was well tolerated in all of the macaques following each of the three injections, with no sign of toxicity, and it generated strong immune responses against the SIV antigens encoded by the vaccine.

Six months after receiving their last injections, the monkeys were exposed rectally to a single, high concentration dose of SIV and then followed closely for 18 months.

Four of the unvaccinated animals died during the 18-month follow-up period, within 17 to 65 weeks following exposure to the virus. The one surviving monkey in the control group was the elite controller. 

Three of the vaccinated animals died, with the first macaque dying at 65 weeks post-vaccination and the third animal dying 77 weeks post-vaccination.

Peak viremia—an initial high-level burst of virus after infection—occurred in all the animals. During the “steady state,” when the virus level decreases and generally maintains itself following peak viremia, SIV remained detectable in the five unvaccinated macaques and three of the vaccinated monkeys that died. The two remaining vaccinated macaques had viral loads that went undetectable. While both monkeys have experienced viral load blips—transient detectable levels—they ended the 18-month follow-up period with undetectable levels of SIV.

The two macaques with undetectable viral loads also had undetectable levels of cell-associated SIV DNA—virus inside cells collected from the blood. In contrast, detectable virus was found in blood cells taken from the macaque elite controller and the macaques that died in the study.

The researchers also measured SIV in the guts of the monkeys, which harbors mucosal tissues rich in immune system cells—and virus in infected humans and primates. One of the two macaques described above had undetectable SIV DNA in intestinal tissue, and another had low-level virus. Levels of SIV DNA were significantly higher in the macaque elite controller and both the vaccinated and unvaccinated animals that died.

As for levels of virus in lymph nodes, detectable SIV DNA was documented in all animals, though the two macaques with undetectable viral loads had significantly lower levels of SIV in their lymph nodes compared with the elite controller and deceased monkeys.

The researchers also evaluated CD4 counts. In the four deceased unvaccinated monkeys, CD4s remained below their pre-infected levels for much of the follow-up. Even among the elite controller macaque, there was a downward trend in the CD4 count over time, ultimately falling below the pre-infected level.

Below-infection CD4 counts were also seen in the three vaccinated monkeys that died during follow-up. One of the two surviving vaccinated macaques has maintained a CD4 count above pre-infection levels, whereas the second has more or less maintained its pre-infected CD4 count.

Why three of the vaccinated macaques experienced obvious disease progression—and whether there were any key virologic or immunologic differences compared with the unvaccinated monkeys—wasn't clear from the data presented by Lemiale's group. 
“Our findings define the achievement of functional cure in a subset of vaccines and warrant clinical investigation, as recently advised by the FDA,” Lemiale and his colleagues concluded. “We are currently finalizing studies, and [VRX1273] is being moved into Phase I clinical trial in a therapeutic setting in HIV-infected subjects. Safety and immunogenicity will be established in this first-in-class, first-in-humans trial.”

Search: VIRxSYS, macaques, monkeys, cure, functional, SIV, VRX1273, VRX116, Lemiale, Rome, IAS

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.